GLP-1 drugs could transform treatment of obstructive sleep apnea in obese adolescents | Research

The takeaway

GLP-1 receptor agonists, proven to reduce adult OSA severity by up to 15% weight loss, are proposed as adjunct therapy for adolescents with severe obesity and obstructive sleep apnea who cannot access or tolerate surgery or CPAP.

Up to 15% weight loss + OSA improvement
Adult GLP-1RA evidence supports exploration in adolescents with severe obesity-related OSA who lack access to surgery or CPAP

What the researchers found

Adult evidence: GLP-1RAs reduce body weight up to 15% and significantly decrease OSA severity. Proposed for adolescents with severe obesity + OSA as adjunct to multidisciplinary care. Addresses access inequity in sleep labs and obesity clinics.

Why it matters

Pediatric obesity and OSA are growing epidemics with limited treatment options. GLP-1 drugs could fill a critical gap for adolescents who cannot access surgery, tolerate CPAP, or achieve weight loss through lifestyle changes alone.

How the study worked

Perspective/opinion article reviewing adult GLP-1RA evidence for OSA and proposing application to adolescents.

What this study cannot tell us

No direct evidence for GLP-1 drugs in pediatric OSA. Adult evidence extrapolated. Long-term safety in growing adolescents uncertain. Cost and access remain barriers.

How to read the evidence

Perspective/opinion based on adult evidence extrapolation. No direct pediatric OSA data for GLP-1 drugs.

When this study was published

Published in 2025.

The bigger picture

This reflects the expanding scope of GLP-1 drugs into pediatric medicine and sleep medicine simultaneously. As evidence builds in both areas, clinical trials for adolescent OSA with GLP-1 drugs seem inevitable.

Questions still open

Will clinical trials of GLP-1 drugs for adolescent OSA be conducted?
What is the optimal age range and BMI threshold for GLP-1 use in pediatric OSA?
Could GLP-1 drugs reduce the need for adenotonsillectomy in obese children?

Common questions

Can GLP-1 drugs help children with sleep apnea?

In adults, GLP-1 drugs reduce both weight and sleep apnea severity. This article proposes they could similarly help obese adolescents with OSA, especially those who cannot access or tolerate surgery or CPAP machines. However, no direct clinical trials in children for this purpose have been completed yet.

Why is pediatric sleep apnea hard to treat?

Many obese adolescents with OSA face multiple barriers: sleep labs are overwhelmed, CPAP is poorly tolerated by young people, weight loss is extremely difficult to sustain, and specialty clinics have long wait times. GLP-1 drugs could offer a more accessible treatment option as part of a comprehensive approach.

Read the original research

Could Glucagon-Like Peptide-1 (GLP-1) receptor antagonists be used to treat obstructive sleep apnoea in children and adolescents with obesity?

Paediatric respiratory reviews

View on PubMed ↗Publisher’s paper ↗

Citation

Silva, Dilan; Baur, Louise; Fitzgerald, Dominic A. (2025). Could Glucagon-Like Peptide-1 (GLP-1) receptor antagonists be used to treat obstructive sleep apnoea in children and adolescents with obesity?. Paediatric respiratory reviews. https://doi.org/10.1016/j.prrv.2025.08.001